CJC-1295 no/DAC + Ipamorelin 10mg Blend

CJC-1295 (No DAC) + Ipamorelin (5/5mg blend)

Synergistic Growth Hormone Modulator

Introduction

The CJC-1295 (No DAC) + Ipamorelin Blend represents a dual-pathway approach to growth hormone (GH) modulation, combining the upstream stimulation of growth hormone–releasing hormone (GHRH) receptors with the downstream activation of ghrelin (GHS-R1a) receptors. This pairing is widely studied for its ability to mimic the body’s natural pulsatile GH secretion, producing synergistic and physiologically balanced effects on growth hormone and IGF-1 output without significant influence on cortisol or prolactin levels.

Mechanism of Action

CJC-1295 (No DAC) — a tetra-substituted analog of GHRH — binds to GHRH receptors on pituitary somatotroph cells, stimulating GH release via cAMP and IP₃-mediated signaling. Its substitutions at amino acid positions 2, 8, 15, and 27 improve resistance to enzymatic degradation, extending half-life to approximately 30 minutes while maintaining natural GH pulsatility.Ipamorelin, a selective GHS, binds to the ghrelin receptor (GHS-R1a) to further enhance GH release. Unlike earlier GHRPs, Ipamorelin shows minimal activity on ACTH and prolactin, providing a clean, targeted GH-releasing profile.When combined, CJC-1295 + Ipamorelin activate complementary receptor systems, amplifying GH pulse amplitude and frequency—often described as producing “layered” GH release that closely mimics physiological secretion patterns.

Research Applications

Growth Hormone Optimization — Dual receptor activation enhances both the signal initiation (CJC-1295) and secretory amplification (Ipamorelin) phases of GH release. Studies show additive increases in circulating GH and IGF-1 levels while preserving natural feedback loops.

Muscle and Tissue Regeneration — Heightened GH and IGF-1 signaling promote protein synthesis, muscle hypertrophy, and collagen turnover, making this blend useful in pre-clinical research on recovery, wound healing, and cellular repair.

Metabolic and Cellular Studies — Ipamorelin’s influence on energy metabolism, combined with CJC-1295’s anabolic profile, provides a unique model for investigating fat oxidation, insulin sensitivity, and mitochondrial biogenesis.

Neuroendocrine and Aging Research — Researchers have observed improved sleep quality, skin elasticity, and subjective well-being markers in trials involving GHRH and GHS combinations. This makes the CJC-Ipamorelin pairing of interest in longevity and neuroendocrine restoration studies.

Half-Life and Synergy

Together, these kinetics produce a synergistic GH wave—rapid onset from CJC-1295 followed by extended stimulation from Ipamorelin.

Key Citations

• Teichman SL et al. J Clin Endocrinol Metab. 2006;91(3):799-805.

• Raun K et al. Eur J Endocrinol. 1998;139(5):552-561.

• Johansen NL et al. Ann N Y Acad Sci. 1998;865:309-316.

• Frohman LA et al. Endocr Rev. 2002;23(3):416-450.

• Svensson J et al. Growth Horm IGF Res. 1999;9(1):10-17.

NOTICE OF COMPLIANCE

The mission of BioGenix Peptides™ is to provide researchers with the highest-quality, Ultra-Pure Series™ compounds to help unlock the full potential of this evolving field. With precision, purity, and scientific integrity at the core of our operations, BioGenix Peptides™ is dedicated to supporting responsible exploration and discovery

Products from BioGenix Peptides™ are not intended for human consumption. They are supplied exclusively for in-vitro and pre-clinical research purposes.

By purchasing or using these products, the Customer accepts full responsibility for their handling and use, and agrees to indemnify and hold BioGenix Peptides™ harmless from any claims resulting from misuse.